AVIGEN(avgn) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVIGEN(avgn)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (178)	9/6/2001 5:55:04 PM
From: JMarcus	Read Replies (1) of 228

Rick, Tom Abate wrote today that the FDA "asked researchers working with Avigen to halt their experiments earlier this year" because of concerns about the Washington University finding (disclosed to the FDA in December) that six out of 59 mice injected with AAV vectors "developed liver cancer after living to what -- for rodents -- would be well into middle age." I don't find any mention of this in any of Avigen's 10Q reports. Isn't that the kind of event that should have been disclosed in a 10Q? My faith in Avigen's management is very tarnished now. I see that the CEO was selling lots of stock in May and June. Things have brightened a bit since the reported insider trades, because the FDA gave Avigen permission in August to start the Phase I Coagulin-B trial, infusing the AAV vector into the hepatic artery. But I'm feeling miffed about the lack of disclosure and insider trading. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next